Skip to Main Content

Good morning. Elizabeth Cooney here, minding the Pharmalittle store today. Ed will be back tomorrow, but here’s what’s brewing today.

After weeks of anticipation, Jacobus Pharmaceutical has priced its rare disease drug at $80 a tablet, or less than half the price of a similar pill sold by its upstart rival, Catalyst Pharmaceuticals (CPRX), STAT informs us. The move is likely to set up a closely watched battle between a small, family-run drug maker that used to supply the drug for free and a newcomer that secured seven years’ patent protection before Jacobus won FDA approval for a pediatric version.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!